Hydroa Vacciniforme

A vesicular and bullous eruption having a tendency to recur in summer during childhood and commonly appearing on sun-exposed skin. The lesions are surrounded by an erythematous zone and resemble a vaccination. (From Dorland, 27th ed)

Networked: 34 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Lymphoproliferative Disorders (Lymphoproliferative Disorder)
2.	T-Cell Lymphoma (Lymphoma, T Cell)
3.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
4.	Lymphoma (Lymphomas)
5.	Solar Urticaria

Experts

1.	Iwatsuki, Keiji: 2 articles (04/2020 - 10/2009)
2.	Cho, Junhun: 1 article (06/2021)
3.	Ko, Young-Hyeh: 1 article (06/2021)
4.	Lee, Dongyoun: 1 article (06/2021)
5.	Lee, Jong Hee: 1 article (06/2021)
6.	Lee, Jongeun: 1 article (06/2021)
7.	Oh, Se Jin: 1 article (06/2021)
8.	Park, Ji-Hye: 1 article (06/2021)
9.	Demirkan, Neşe: 1 article (12/2020)
10.	Duygulu, Şeniz: 1 article (12/2020)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hydroa Vacciniforme:

1.	Fish OilsIBA 03/01/2001 - "[Hydroa vacciniforme: dietary fish oil]." 01/01/1998 - "We report for the first time the response of hydroa vacciniforme to dietary fish oil. " 01/01/1998 - "Dietary fish oil as a photoprotective agent in hydroa vacciniforme." 03/01/2001 - "We report a case of hydroa vacciniforme treated successfully with dietary fish oil (Maxepa(R)). "
2.	Intravenous Immunoglobulins (IVIG)FDA Link 06/18/2020 - "Hydroa Vacciniforme-like Lymphoproliferative Disorder Treated with Intravenous Immunoglobulin: Long-term Remission Without Haematopoietic Stem Cell Transplantation or Chemotherapy."
3.	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/01/2012 - "Efficacy of ω-3 polyunsaturated fatty acids for the treatment of refractory hydroa vacciniforme."
4.	MaxepaIBA 03/01/2001 - "We report a case of hydroa vacciniforme treated successfully with dietary fish oil (Maxepa(R)). "
5.	DNA (Deoxyribonucleic Acid)IBA 10/01/1985 - "Abnormally low UV-induced unscheduled DNA synthesis in cells from a patient with hydroa vacciniforme." 06/01/2021 - "Hydroa Vacciniforme-Like Lymphoproliferative Disorder in Korea: Prognostic Implication of Clinical Signs and Whole Blood Epstein-Barr Virus DNA." 01/01/2019 - "Patients with classic hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) typically have high levels of Epstein-Barr virus (EBV) DNA in T cells and/or natural killer (NK) cells in blood and skin lesions induced by sun exposure that are infiltrated with EBV-infected lymphocytes. " 12/01/2020 - "In this report, we analyzed the EBV DNA load in the peripheral blood mononuclear cells (PBMCs) and plasma of patients with hydroa vacciniforme (HV) and/or hypersensitivity to mosquito bites (HMB) to understand the clinical significance of EBV DNA load. " 12/01/2020 - "The aim of the measurement of Epstein-Barr virus DNA in hydroa vacciniforme and hypersensitivity to mosquito bites."
6.	Antiviral Agents (Antivirals)IBA 11/24/2014 - "Antiviral treatment of a boy with EBV-associated hydroa vacciniforme." 12/01/2020 - "Epstein-Barr virus-associated hydroa vacciniforme-like lymphoproliferative syndrome: excellent response to antiviral therapy." 01/01/2009 - "Antiviral therapy in children with hydroa vacciniforme."
7.	Thalidomide (Thalomid)FDA Link 12/01/2014 - "Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru." 07/01/2022 - "We report a case of a patient who developed hydroa vacciniforme-like lymphoma (HVLL, an EBV-peripheral T-cell lymphoma), refractory to multiple lines of systemic therapy including methotrexate, mycophenolate mofetil, dapsone, thalidomide, prednisone, and romidepsin. "
8.	para-AminobenzoatesIBA 07/01/1953 - "Hydroa vacciniforme treated with potassium para-aminobenzoate."
9.	A-Form DNA (A-DNA)IBA 01/01/2023 - "The Epstein-Barr virus (EBV) is a DNA virus that infects 90% of the human population, is responsible for certain cutaneous lymphomas (extranodal NK/T-cell lymhoma, hydroa vacciniforme lymphoproliferative disorder, lymphomatoid granulomatosis, others), and can be associated with a variety of cutaneous manifestations (eg, infectious mononucleosis, severe mosquito bite allergy, chronic active EBV disease, Gianotti-Crosti syndrome). "
10.	beta Carotene (Betacarotene)FDA Link 01/01/1995 - "Hydroa vacciniforme treated by a combination of beta-carotene and canthaxanthin."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/1988 - "Permanent cure of hydroa vacciniforme after chemotherapy for Hodgkin's disease." 06/18/2020 - "Hydroa Vacciniforme-like Lymphoproliferative Disorder Treated with Intravenous Immunoglobulin: Long-term Remission Without Haematopoietic Stem Cell Transplantation or Chemotherapy."
2.	Stem Cell Transplantation 06/18/2020 - "Hydroa Vacciniforme-like Lymphoproliferative Disorder Treated with Intravenous Immunoglobulin: Long-term Remission Without Haematopoietic Stem Cell Transplantation or Chemotherapy."
3.	Immunotherapy 05/01/2011 - "Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy."
4.	Therapeutics 08/01/1982 - "Hydroa vacciniforme: diagnosis and therapy." 07/01/2009 - "To study the clinical features, diagnosis and therapy of hydroa vacciniforme-like cutaneous T cell lymphoma. " 01/01/2022 - "Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection." 12/01/2020 - "Epstein-Barr virus-associated hydroa vacciniforme-like lymphoproliferative syndrome: excellent response to antiviral therapy." 01/01/2009 - "Antiviral therapy in children with hydroa vacciniforme."
5.	Breast Implants (Breast Implant) 03/01/2019 - "Chief among these are Epstein-Barr virus-associated lymphoproliferative disorders such as Epstein-Barr virus-associated mucocutaneous ulcer and hydroa vacciniforme-like lymphoproliferative disorder, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, primary cutaneous acral CD8+ T-cell lymphoma, primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, and breast implant-associated anaplastic large cell lymphoma. "